Comparative Pharmacology
Head-to-head clinical analysis: ALUPENT versus METAPROTERENOL SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUPENT versus METAPROTERENOL SULFATE.
ALUPENT vs METAPROTERENOL SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle, leading to bronchodilation.
Selective beta-2 adrenergic receptor agonist that activates adenylate cyclase, increasing intracellular cyclic AMP leading to bronchodilation and inhibition of mast cell mediator release.
Inhalation: 2 inhalations (0.65 mg per inhalation) every 3-4 hours, up to 12 inhalations per day. Oral: 20 mg three to four times daily.
2.5 mg (0.25 mL of 1% solution) by nebulization every 6-8 hours. For oral, 20 mg every 6-8 hours.
None Documented
None Documented
The terminal elimination half-life of metaproterenol (Alupent) is approximately 2.5–5 hours after oral administration, and 2–4 hours after intravenous or inhaled routes. Its relatively short half-life supports dosing every 4–6 hours for bronchodilator effect.
Terminal elimination half-life: 2-6 hours. Clinical context: Shorter half-life requires frequent dosing; prolongation in renal impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 40-60% of the dose, with the remainder eliminated via biliary/fecal routes. Following oral administration, about 30-40% is recovered in urine as unchanged drug and glucuronide conjugates, and 50-60% in feces. After intravenous administration, renal elimination is 40-50% unchanged, with biliary excretion contributing 30-40%.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist